Show simple item record

dc.contributor.author Warnez, Stephanie
dc.contributor.author Alessi-Severini, Silvia
dc.date.accessioned 2014-04-25T11:06:52Z
dc.date.available 2014-04-25T11:06:52Z
dc.date.issued 2014-04-07
dc.identifier.citation BMC Psychiatry. 2014 Apr 07;14(1):102
dc.identifier.uri http://hdl.handle.net/1993/23558
dc.description.abstract Abstract Background Clozapine effectiveness in the treatment of refractory schizophrenia has been sustained by published evidence in the last two decades, despite the introduction of safer options. Discussion Current clinical practice guidelines have strongly recommended the use of clozapine in treatment-resistant schizophrenia, but prescribing trends do not appear to have followed such recommendations. Clozapine is still underutilized especially in patients at risk of suicide. It seems that physicians are hesitant in prescribing clozapine due to concerns about serious adverse effects. Recent reports have highlighted the need to inform health professionals about the benefits of treating patients with clozapine and have voiced concerns about the underutilization of clozapine especially in patients at risk of suicide. Summary Guidelines and prescribing patterns reported in various countries worldwide are discussed. Suggestions on how to optimize clozapine utilization have been published but more efforts are needed to properly inform and support prescribers’ practices.
dc.title Clozapine: a review of clinical practice guidelines and prescribing trends
dc.type Journal Article
dc.language.rfc3066 en
dc.description.version Peer Reviewed
dc.rights.holder Stephanie Warnez et al.; licensee BioMed Central Ltd.
dc.date.updated 2014-04-25T11:06:52Z
dc.identifier.doi http://dx.doi.org/10.1186/1471-244X-14-102


Files in this item

This item appears in the following Collection(s)

  • Research Publications [1126]
    This collection contains full text research publications authored or co-authored by University of Manitoba researchers.

Show simple item record

View Statistics